We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.
- Authors
Schrenk, Karin G.; Weschenfelder, Wolfram; Spiegel, Christian; Agaimy, Abbas; Stöhr, Robert; Hartmann, Arndt; Gaßler, Nikolaus; Drescher, Robert; Freesmeyer, Martin; Malouhi, Amer; Bürckenmeyer, Florian; Aschenbach, René; Teichgräber, Ulf; Kögler, Christine; Vogt, Matthias; Hofmann, Gunther O.; Hochhaus, Andreas
- Abstract
With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET-fusion-associated sarcomas. As new targeted therapies are under development, similar treatment options may become available for sarcoma patients.
- Subjects
NEOADJUVANT chemotherapy; SARCOMA; NUCLEOTIDE sequencing
- Publication
Journal of Cancer Research & Clinical Oncology, 2023, Vol 149, Issue 9, p5493
- ISSN
0171-5216
- Publication type
Article
- DOI
10.1007/s00432-022-04496-y